Tuesday 5 November 2024

The Pharma Letter Podcast — Episode 12 — Mastering the microbiome

Biotechnology
Simon Wentworth
9 March 2022
episode12-b

More on this story...

Biotechnology
Takeda leads Big Pharma in microbiome-targeting treatments
17 August 2021
Biotechnology
Third clinical program bought by AI-based microbiome specialist
27 April 2022
Biotechnology
Seres Therapeutics falls despite positive Phase III results with SER-109
24 May 2022
Biotechnology
MaaT Pharma partners with Skyepharma on microbiome production
9 February 2022


Companies featured in this story

More ones to watch >


Today's issue

Boehringer mental health tie-up worth up to $126.5 million to Broad Institute
Pharmaceutical
Boehringer mental health tie-up worth up to $126.5 million to Broad Institute
4 November 2024
Biotechnology
Frits van Alphen gets Memo CDO job
4 November 2024
Pharmaceutical
FDA accepts Ionis NDA for donidalorsen
4 November 2024
Pharmaceutical
Disc Medicine leaps as it gets positive FDA feedback
4 November 2024
Biotechnology
Ascendis and Novo Nordisk sign deal on metabolic and CV diseases
4 November 2024
Pharmaceutical
Immunology to take front seat at Kymera
4 November 2024
Biotechnology
BioNTech posts better-than-expected 3rd-qtr 2024 results
4 November 2024

Company Spotlight

A biopharma company developing products for the treatment of human disease, including immunology, metabolism, cardiology and ophthalmology.




More Features in Biotechnology

Frits van Alphen gets Memo CDO job
4 November 2024
Ascendis and Novo Nordisk sign deal on metabolic and CV diseases
4 November 2024
BioNTech posts better-than-expected 3rd-qtr 2024 results
4 November 2024
Dutch start-up Tessellate BIO names Lara Boyd as CBO
4 November 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze